Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries

Sponsored:

Wednesday, October 11, 2023

Spinal cord injuries (SCI) can be devastating, and they can lead to a loss of mobility, sensation, and independence. There is no cure for SCI, and the treatments that are available are often limited and expensive.

However, it is important to remember that there is hope. Researchers are making progress in developing new treatments with innovative technology across the therapeutic spectrum, presenting the potential to help people suffering SCI to live full and productive lives and investors the chance to benefit through their support.

ReWalk Robotics Ltd. (Nasdaq: RWLK) is taking an outside-in approach with its FDA-cleared wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with SCI to stand upright, walk, turn, and climb and descend stairs. Lineage Cell Therapeutics (NYSE American: LCTX) is developing OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute SCI. NervGen Pharma Corp. (TSX-Venture: NGEN) (OTCQX: NGENF) recently hit a milestone with the first SCI patient treated in a Phase 1b/2a proof-of-concept clinical trial evaluating its NVG-291 drug candidate. 

As measured by valuations, investors appreciate the drug development pathway, considering LCTX and NGEN both command market capitalizations in excess of $100 million ($200 million for LCTX). That shines a light on NurExone Biologic Inc. (TSX-Venture: NRX), an upstart pharmaceutical company on a mission to reverse the devastating effects of nervous system injuries.

Under an exclusive worldwide license from the Technion and Tel Aviv University, NurExone is developing the ExoTherapy platform for next generation therapies utilizing exosomes as nanocarriers to deliver therapeutic molecules in the body creating a healing environment through neuron rewiring and regeneration. Exosomes are ubiquitous in the body, released by cells into the extracellular matrix where they transport a variety of molecules, including proteins, nucleic acids, lipids, and metabolites, from the parent cell to other cells. Exosomes are thought to play a critical role in cell-to-cell communication, signaling, and other cellular processes. 

The first drug candidate from the ExoTherapy technology is ExoPTEN, a new treatment for acute SCI. ExoPTEN is made up of exosomes that have been loaded with PTEN siRNA, a small interfering RNA molecule that can silence the PTEN (phosphatase and tensin homolog) gene. This is a gateway to new therapies, as lab research indicates that inhibition of PTEN can play a role in axon regeneration in cases of SCI.

The early work is extremely compelling. NurExone’s proprietary drug reversed paralysis in laboratory rats, enabling them to walk again. The company, which went public in July 2022, believes that this paralysis reversal in animal models is replicable in humans. While that type of revolutionary result would likely be embraced regardless of delivery method, ExoPTEN is delivered via a non-invasive process.

NurExone is aiming for filing an investigational new drug (IND) application during 2024 to initiate clinical trials for ExoPTEN.

Going forward, the company envisions using the ExoTherapy platform technology for producing and loading quality exosomes for an array of indications. The growth plan includes new technologies and IP that may be licensed and spun off by others, driving early revenues and creating value for shareholders in NurExone. In the interim, the company will keep pushing the edge of medicine and biology with a square focus on SCI.

Over the last month, shares of NRX have climbed 25 percent.

-- 

NurExone Biologic Inc. (TSX-Venture: NRX) Full Corporate Write-Up: Click Here.

--

About AllPennyStocks.com:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.

As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.

Sponsored: